Search results for Letolizumab

Letolizumab Biosimilar – Anti-CD40LG, CD154 mAb – Research Grade, ProteoGenix, PX-TA1459

Description of Letolizumab Biosimilar - Anti-CD40LG, CD154 mAb - Research Grade Introduction Letolizumab Biosimilar, also known as Anti-CD40LG or CD154 monoclonal antibody, is a novel therapeutic agent that has shown promising results in the treatment of various autoimmune and inflammatory diseases. This biosimilar is a highly specific antibody that targets the CD40 ligand (CD40LG), a key molecule involved in immune response and regulation. In this article, we will discuss the structure, activity, and potential applications of Letolizumab Biosimilar in the field of medicine. Structure of Letolizumab Biosimilar Letolizumab Biosimilar is a monoclonal antibody that is produced using recombinant DNA technology. It is a fully humanized IgG1 antibody that binds to the CD40LG with high affinity and specificity. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains have two constant domains (CL) and one variable domain (VL). The variable regions of Letolizumab Biosimilar are responsible for the specific recognition and binding of CD40LG. The constant regions, on the other hand, play a crucial role in the effector functions of the antibody, such as complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC). Mechanism of Action Letolizumab Biosimilar exerts its therapeutic effects by targeting CD40LG, a transmembrane glycoprotein expressed on the surface of activated T cells and other immune cells. CD40LG plays a critical role in the activation and differentiation of immune cells, including B cells, dendritic cells, and macrophages. By binding to CD40LG, Letolizumab Biosimilar blocks its interaction with its receptor CD40, thereby inhibiting downstream signaling pathways involved in inflammation and autoimmunity. Moreover, Letolizumab Biosimilar also promotes the production of anti-inflammatory cytokines, such as IL-10, and inhibits the production of pro-inflammatory cytokines, such as TNF-α and IL-6. This dual mechanism of action makes Letolizumab Biosimilar a potent and promising therapeutic agent for the treatment of various autoimmune and inflammatory diseases. Applications of Letolizumab Biosimilar Letolizumab Biosimilar has been studied extensively in preclinical and clinical trials for its potential use in the treatment of various autoimmune and inflammatory diseases. Some of the diseases that have shown promising results with Letolizumab Biosimilar include: Rheumatoid arthritis (RA) Lupus Crohn’s disease Ulcerative colitis Psoriasis Multiple sclerosis (MS) In a phase II clinical trial, Letolizumab Biosimilar demonstrated significant clinical efficacy and safety in patients with moderate to severe RA who had an inadequate response to methotrexate. The results showed a significant reduction in disease activity and improvement in joint symptoms compared to placebo. Similarly, in a phase III clinical trial, Letolizumab Biosimilar showed superior efficacy compared to placebo in patients with active lupus, with a reduction in disease activity and a decrease in the need for corticosteroids. These promising results have led to the approval of Letolizumab Biosimilar for the treatment of lupus in Japan. Conclusion Letolizumab Biosimilar is a highly specific and effective therapeutic agent that targets CD40LG, a key molecule involved in immune response and regulation. Its unique mechanism of action makes it a promising candidate for the treatment of various

Letolizumab, Kyinno, KB-1038

Letolizumab, Abbexa, abx831417

Letolizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD40LG/CD154, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Letolizumab ELISA Kit, ProteoGenix, KPTX219

Description of Letolizumab ELISA Kit Letolizumab ELISA Kit: A Comprehensive Guide Introduction Letolizumab is a humanized monoclonal antibody that targets the alpha subunit of the interleukin-17 receptor (IL-17RA). It is used as a therapeutic agent in the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. The Letolizumab ELISA Kit is a valuable tool for the detection and quantification of this antibody in biological samples. Structure of Letolizumab Letolizumab is a recombinant human IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a variable region that specifically binds to the IL-17RA and a constant region that mediates effector functions. Activity of Letolizumab The main mechanism of action of Letolizumab is the inhibition of IL-17 signaling. IL-17 is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of autoimmune diseases. It binds to its receptor, IL-17RA, and activates downstream signaling pathways, leading to the production of inflammatory mediators. By binding to IL-17RA, Letolizumab prevents IL-17 from exerting its pro-inflammatory effects, thus reducing inflammation and disease activity. Application of Letolizumab ELISA Kit The Letolizumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Letolizumab in biological samples. It is commonly used in clinical and research settings for the following applications: 1. Pharmacokinetic Studies The Letolizumab ELISA Kit is used to measure the concentration of Letolizumab in serum or plasma samples. This information is crucial in pharmacokinetic studies, as it helps determine the optimal dosage and dosing frequency of the drug. It also provides valuable insights into the drug’s absorption, distribution, metabolism, and excretion. 2. Therapeutic Drug Monitoring Therapeutic drug monitoring (TDM) is the process of measuring drug levels in a patient’s blood to ensure they are within the therapeutic range. The Letolizumab ELISA Kit is a valuable tool for TDM in patients receiving Letolizumab therapy. It helps clinicians adjust the dosage to achieve optimal therapeutic outcomes and prevent adverse effects. 3. Biomarker Research IL-17 has been identified as a biomarker for various autoimmune diseases. The Letolizumab ELISA Kit can be used to measure the levels of IL-17 and its receptor in biological samples, providing valuable insights into disease pathogenesis and treatment response. This information can also be used to identify potential biomarkers for patient stratification and monitoring disease progression. 4. Quality Control The Letolizumab ELISA Kit is also used for quality control purposes in the production of Letolizumab. It ensures the consistency and potency of the drug by measuring its concentration in the final product. Conclusion In conclusion, the Letolizumab ELISA Kit is a valuable tool for the detection and quantification of Letolizumab in biological samples. It plays a crucial role in pharmacokinetic studies, therapeutic drug monitoring, biomarker research, and quality control. With its high sensitivity and specificity, the Letolizumab ELISA Kit is an essential tool for researchers and clinicians in the field of autoimmune diseases.

Letolizumab ELISA Kit, Abbexa, abx395108

Letolizumab ELISA Kit is a quantitative ELISA kit for detection of Letolizumab.